Saurabh Saha Sells 14,656 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 14,656 shares of the firm's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $12.29, for a total value of $180,122.24. Following the sale, the chief executive officer now owns 261,361 shares in the company, valued at $3,212,126.69. This trade represents a 5.31 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Saurabh Saha also recently made the following trade(s):

  • On Thursday, March 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.69, for a total value of $917,950.00.
  • On Thursday, February 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.93, for a total value of $876,150.00.

Centessa Pharmaceuticals Price Performance




Centessa Pharmaceuticals stock opened at $12.67 on Wednesday. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $1.69 billion, a P/E ratio of -8.28 and a beta of 1.53. The firm has a fifty day moving average of $14.62 and a 200-day moving average of $15.92. Centessa Pharmaceuticals plc has a 52-week low of $7.75 and a 52-week high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.04. As a group, analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of CNTA. GF Fund Management CO. LTD. purchased a new stake in shares of Centessa Pharmaceuticals during the fourth quarter valued at approximately $31,000. GAMMA Investing LLC lifted its holdings in Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after buying an additional 865 shares in the last quarter. Barclays PLC lifted its holdings in Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after buying an additional 4,952 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in Centessa Pharmaceuticals in the 4th quarter valued at about $162,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Centessa Pharmaceuticals during the fourth quarter valued at about $171,000. 82.01% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Morgan Stanley reiterated an "overweight" rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating on the stock. Guggenheim reissued a "buy" rating and set a $28.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Finally, Piper Sandler assumed coverage on Centessa Pharmaceuticals in a report on Monday, March 31st. They set an "overweight" rating and a $38.00 price objective for the company. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $27.71.

View Our Latest Analysis on CNTA

Centessa Pharmaceuticals Company Profile

(Get Free Report)

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

Read More

Insider Buying and Selling by Quarter for Centessa Pharmaceuticals (NASDAQ:CNTA)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.

Insider Buying or Selling at Centessa Pharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Centessa Pharmaceuticals and related companies.
More From MarketBeat
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles